newsio aggregates and links to original sources. We do not own the original images or content. If you believe content infringes on intellectual property rights, contact us — it will be removed at first notice.
business/news//Seeking Alpha
InMed and Mentari announce all-stock merger deal to create a new entity that will trade on Nasdaq under a new ticker.
InMed Pharmaceuticals and Mentari Therapeutics have agreed to an all-stock merger deal.
KEY POINTS
The merged company will trade on Nasdaq under a new ticker symbol.
This merger caused InMed Pharmaceuticals' stock price to rise approximately 170% in premarket trading.
Mentari Therapeutics specializes in developing drugs for migraines.
InMed and Mentari announce all-stock merger deal
May 19, 2026, 8:51 AM ETInMed Pharmaceuticals Inc. (INM) StockBy : Dulan Lokuwithana, SA News Editor
Comments
Canadian pharmaceutical company InMed Pharmaceuticals (INM) added ~170% in the premarket on Tuesday after announcing an all-stock merger agreement with migraine drug developer Mentari Therapeutics to create a new entity that will trade on Nasdaq under a new ticker.
Waltham, Massachusetts-based
Newsletters for Every Investor
Get daily, sector-specific newsletters packed with expert insights, fresh ideas, and new opportunities.
Subscribe to Newsletters